ANDA 76781, held by Hikma Farmaceutica. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 76781 (Ondansetron Hydrochloride), held by Hikma Farmaceutica, was first approved by FDA on Dec 26, 2006, with 8 approved supplements and 0 published complete response letters.
Ondansetron Injection, USP is a 5-HT 3 receptor antagonist indicated for the prevention of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Apr 8, 2026 | Supplement 20Labeling · Standard review | Approved | None posted |
| Apr 26, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Apr 26, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 20, 2014 | Supplement 11Labeling · Standard review | Approved | None posted |
| Dec 20, 2014 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 19, 2013 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 30, 2012 | Supplement 9Labeling | Approved | None posted |
| Jan 31, 2011 | Supplement 7Labeling | Approved | None posted |
| Dec 26, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters